Tag archive for ‘Johnson & Johnson (NYSE:JNJ)’

What Johnson & Johnson (NYSE:JNJ) Now Thinks About Doing Business In China

by Rahul Sharma - on Nov 10th 2014 - No Comments

Tomahawk, WI 11/10/2014 (Basicsmedia) – In an interview on CNBC, Johnson & Johnson (NYSE:JNJ)’s Chairman and CEO, Alex Gorsky, outlined their opportunities in China. The company is interested in expanding its operations in China, especially in meeting currently unmet medical needs. The CEO also touched tax inversion but downplayed...

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), Sarepta Therapeutics Inc. (NASDAQ:SRPT), GlaxoSmithKline plc (ADR) (NYSE:GSK) Surging on Hope of Ebola Prospective Drugs

by Cyrus Emen - on Aug 12th 2014 - No Comments

Tomahawk, WI 08/12/2014 (Basicsmedia) – The ongoing Ebola crisis has been the longest and largest, flipping the script on the disease containment seen by the U.S and Spain flowing some of their infected nationals from West Africa. The contagious disease has aroused a number of ethical issues on the fact that drugs developed by pharmaceutical...

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s Sellout May Be The Next Big News After The IDIX-Grab

by Sally Murdock - on Jun 12th 2014 - No Comments

Tomahawk, WI 06/12/2014 (Basicsmedia) – Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has powered up from 2.88 to 7.29, almost 169% in this week’s trade activity. Investors smell an anticipated sellout of ACHN to some bigger health care or pharmaceutical firm, as a key industry players are targeting the exquisite Hepatitis C drug...

Gilead Sciences, Inc. (NASDAQ:GILD): Rising Sales And More Good News

by Krisha Talati - on Jun 10th 2014 - No Comments

Tomahawk, WI 06/10/2014 (Basicsmedia) – Gilead Sciences, Inc. (NASDAQ:GILD) is on a bit of a roll with its share prices having risen by 253.93% in the last five years and 49.15% in the last one year. With a blockbuster drug like Sovaldi generating billions in sales and multiple drug candidates in the pipeline — Cobicistat and Elvitegravir...

Johnson & Johnson (NYSE:JNJ): Facing Patent Expirations Head on

by Rahul Sharma - on Feb 24th 2014 - No Comments

Tomahawk, WI 2/24/2014 (Basicsmedia) – Patent expirations are a big headache for most of the big pharmaceutical giants including Johnson & Johnson (NYSE:JNJ). They have grown accustomed to the market realities through patent protection that protected their markets and allowed them to charge rates at their own will. JNJ’s Patent...

Gilead Sciences, Inc. (NASDAQ:GILD)’s Hepatitis C Drug Gets Approved By FDA – ABBV,JNJ, BMY

by Cyrus Emen - on Dec 10th 2013 - No Comments

Tomahawk, WI 12/10/2013 (BasicsMedia) – Gilead Sciences, Inc. (NASDAQ:GILD) got approval for a drug, Sovaldi, for hepatitis C. This approval was very much expected. As this drug works faster than most of the drugs on the market with very few side effects, it may produce more than $6 billion in annual sales. The first all-oral combination...

Reasons Why Johnson & Johnson (NYSE:JNJ)’s Results Are Consistent

by Sally Murdock - on Oct 16th 2013 - No Comments

Tomahawk, WI 10/16/2013 (BasicsMedia) – Johnson & Johnson (NYSE:JNJ) is a developer of a wide range of health care products. It researches, develops, manufactures and sells all these products. Around 500 companies that operate in 60 countries all over the world carry out its operations. More than that is the fact that the company’s...

Berkshire Hathaway (NYSE:BRK-A): Industrial Stocks in – Consumer Out (PCP, DE)

by Kenneth Hall - on Nov 15th 2012 - No Comments

Northern, WI 11/15/2012 (BasicsMedia)  —  Berkshire Hathaway (NYSE:BRK-A): Industrial Stocks in – Consumer Out  as Warren makes a portfolio shift, and when he does this it’s like the old E.F.  Hutton commercial when everyone stops what they are doing and gets within earshot of the E.F.  Hutton broker eating lunch…just...